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Abstract 1 
The crystallization of biopharmaceuticals can be problematic since, because the biosynthesis 2 
of these compounds is very difficult to control, they can present a significant amount of 3 
impurities that has to be eliminated. In fact, impurities can lead to changes in the properties of 4 
the drug that can significantly reduce its effectiveness or even put in danger the user.  5 
The substance used in this work is vitamin B12 crude product extracted from fermentation. 6 
The aim of this work is to exploit process analytical technology (PAT) tools to study the 7 
crystallization step of vitamin B12. Linear cooling crystallization experiments were 8 
performed using different conditions. The effects of solvent, cooling rate, seeding and purity 9 
of the initial material on the final size distribution and purity of the crystals were investigated 10 
through the use of UV/Vis spectroscopy, focused beam reflectance measurement (FBRM) 11 
and the CryPRINS software (Crystallization Process Informatics System). 12 
It was found that impurities strongly inhibit the growth of vitamin B12 crystals, promoting 13 
nucleation and leading to a poor final crystal size distribution. Slow cooling can help in 14 
increasing the purity of the final product but also generates a broad crystal size distribution 15 
because of secondary nucleation. Preparing the solution with material already crystallized 16 
once and using purified seeds helped in obtaining a narrower crystal size distribution and also 17 
reduces breakage. 18 
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Introduction 1 
Over the last decade the investment in research and development of biopharmaceutical 2 
companies has more than doubled: there is a great interest in formulating and optimizing the 3 
manufacturing of bio-molecules and biopharmaceuticals such as proteins, lipids, vitamins, 4 
hormones and DNA. Those compounds can be used in the treatment of serious diseases or 5 
just as nutritional supplement.  6 
Vitamin B12 (cobalamin) is one of the biggest and most complex vitamins and, in humans, it 7 
is required to assist the actions of two enzymes: methionine synthase and (R)-methylmalonyl-8 
CoA mutase. It is commonly used to cure pernicious anemia and its deficiency determines an 9 
increase in homocysteine levels that leads to a major risk for heart disease, stroke, 10 
atherosclerosis and vascular diseases. Despite the lack of solid evidences on the importance 11 
of vitamin B12 in maintaining normal myelination of nerve cells, its role in preventing many 12 
neurological and psychiatric symptoms is becoming clearer and clearer. For these reasons, 13 
every year, around 10 tons of the semisynthetic version of vitamin B12 (cyanocobalamin) are 14 
produced by biofermentation from several bacterial species.1  15 
A schematic of vitamin B12 molecule is shown in Figure 1. The molecule is fairly large and 16 
complex and can be divided in three parts: (1) a central corrin ring which contains four 17 
ligands for the central cobalt ion, (2) a lower ligand donated by the 5,6-18 
dimethylbenzimidazole (DMBI) and (3) an upper ligand made from either an adenosyl group 19 
or a methyl group. 20 
Two pseudo-polymorphic forms were discovered by X-ray diffraction: a wet and a dry 21 
crystalline structure.2,3  The main difference between the two is the presence of water 22 
molecules in the crystal lattice that makes the unit cell of the wet form bigger than the dry. 23 
Cyanocobalamin is mainly produced by biosynthetic fermentation processes, although a full 24 
chemical synthesis (consisting of 70 steps) was developed in the early 70s.1  High levels of 25 
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impurities are present in the biosynthesized vitamin B12 that can inhibit growth of the 1 
crystals and strongly affect the final crystal size distribution together with the ease of 2 
downstream processes (filtration in particular).  3 
Process analytical technology (PAT) tools are widely used for the development of the 4 
crystallization processes of many synthetic pharmaceuticals.4-6. The term PAT  refers to “a 5 
system for designing, analyzing, and controlling manufacturing trough timely measurement 6 
of critical quality and performance attributes of raw and in-process material and processes, 7 
with the goal of ensuring final product quality”.7  PAT tools are the main element used in the 8 
“Quality by Design” (QbD) approach that was introduced in the pharmaceutical industries in 9 
order to minimize product waste due to mistakes in the manufacturing process. The QbD 10 
concept consists in obtaining the desired quality of the product though the correct design of 11 
the manufacturing process. In this approach some critical variables of the process, strictly 12 
related to the quality of the product, are controlled during the manufacturing in order to 13 
control the quality of the product itself.8,9  The QbD approach is well known and applied in 14 
the pharmaceutical industry but only few examples are present for the manufacturing of 15 
biopharmaceuticals.10,11  Despite the difficulty of controlling biological processes Near 16 
infrared (NIR) and Raman spectroscopy, HPLC and image analysis were recently used for 17 
some manufacturing steps of biomolecules.12-14  18 
In this work the crystallization of vitamin B12 will be studied with PAT tools (ATR-UV/Vis, 19 
FBRM and CryPRINS) and the effect of impurities on the growth and nucleation rate will be 20 
analyzed. The produced crystals are analyzed with optical microscopy, HPLC and Raman. 21 
Most of the impurities in cyanocobalamin have high levels of fluorescence and, therefore, 22 
Raman can give an indication of the purity of the crystals since it is highly sensitive to this 23 
phenomenon.15,16 However, for a precise quantification of the type and level of impurity in 24 
vitamin B12 samples HPLC is necessary. The paper provides one of the first comprehensive 25 
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case studies that illustrate how an array of PAT tools can be used for the systematic 1 
understanding and design of a biopharmaceutical crystallization process. 2 
 3 
Materials and methods 4 
Equipment 5 
Crude Vitamin B12 produced by fermentation was donated by Hebei Welcome 6 
Pharmaceutical Co., LTD (China). The raw material consisted in a dry powder containing 7 
around 7% of impurities. Those were mainly byproducts of the fermentation process (e.g. 50-8 
carboxyl cyanocobalamin, 34-methyl cobalamin, 8-epi-cyanocobalamin and 9 
cyanocobalaminic lactate) and inert.  Ultrapure water was obtained via a Millipore ultra-pure 10 
water system while ethanol was purchased by Fisher Scientific (purity >95% v/v). Pure water 11 
or solutions of water and ethanol were used as solvents for the experiments. 12 
Experiments were conducted at both Loughborough University, UK and Purdue University, 13 
USA with similar, but not exactly identical instruments. Two 500 ml glass jacketed vessels 14 
and the same Raman system (an RXN1 Raman analyzer with immersion probe and 785 nm 15 
laser, Kaiser with iC Raman 4.1 software) were used. A simple schematic of the rig used for 16 
the experiments is shown in Figure 2. The experiments at Loughborough University were 17 
performed using an MSC621 Carl Zeiss ATR-UV/Vis spectrophotometer with Hellma ATR 18 
(type 661.822-UV) probe and a LabView based in-house software, a D600L Lasentec FBRM 19 
probe (Mettler Toledo with FBRM software V 6.7.0) and a Huber Ministat CC3 20 
thermoregulator. The data from the FBRM, ATR-UV/Vis and the Huber is transmitted in 21 
real-time to the CryPRINS software (Crystallization Process Informatics System). This 22 
allows real-time monitoring and control of the FBRM counts, ATR-UV/Vis signal and the 23 
temperature, as well as setting a temperature profile and performing different control 24 
strategies. The instrumentation at Purdue University consisted in a Zeiss MCS621 UV/Vis 25 
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spectrophotometer with UV-VIS 190-720 nm Zeiss probe (Zeiss ProcessXplorer software 1 
version 1,3-Build 1.3.1.30), an FBRM G400 0.5-2000microns (Mettler Toledo with ic.FBRM 2 
software version 4.3) and a JULABO F25-ME thermoregulator. The samples of vitamin 3 
produced were analyzed using a Raman RXN1 microprobe (Kaiser) and an HPLC Agilent 4 
1100 series (Hewlett Packard) with ChemStation software rev. A.09.03[1417]. 5 
Procedure for linear cooling experiments 6 
Mixtures of water and ethanol and pure water were used as solvents for the linear cooling 7 
experiments. The concentrations used were about 0.118-0.13 g/g solvent in water and ethanol 8 
(saturation temperature of about 50 °C) and between 0.09 and 0.11 g/g solvent for water 9 
(saturation temperature of about 60 °C). The material was dissolved and the hot solution was 10 
filtered (using a filter paper) before starting the cooling profile because of the presence of 11 
insoluble particles in the raw material. The solubility of vitamin B12 in water at different 12 
temperatures was provided by the supplying company and is shown in Table 1, while data for 13 
ethanol/water mixtures at different temperatures was not available from the literature and the 14 
amount of material donated was too small to accurately measure it. However, two inferential 15 
curves of the solubility expressed as UV signal (absorbance value at 361 nm) were obtained 16 
in order to compare two solvents. Those curves can also be directly compared with the UV 17 
data in the Results and Discussion section (which is actually an absorbance and not a 18 
concentration value). The curves were acquired by slow heating (0.075 °C/min) of two 19 
slurries of vitamin B12 in water and ethanol/water. The amount of vitamin dissolved at any 20 
time and temperature is proportional to the absorbance value recorded. Figure 3 shows the 21 
inferential curves as well as the exact solubility in the two solvents at high temperatures (120 22 
g/L ethanol/water solution at 53 °C, and 84 g/L water at 62 °C). The material was added to 23 
the solvent at ambient temperature and then dissolved by heating the solution and keeping it 24 
at high temperature for 15-20 min. In ethanol and water the higher temperature was around 25 
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75 °C while in pure water it was around 70 °C. Four cooling rates were used: -0.075, -0.1, -1 
0.5 and -1 °C/min (slower, slow, fast and faster cooling), both seeded and unseeded 2 
experiments were performed. The cooling rates were chosen based on experience with similar 3 
types of crystals, equipment and scale.19-21 The final temperature after cooling was 5-6 °C. In 4 
the case of the seeded experiments the mass of seeds was of about 2.5 % of the total solid 5 
dissolved in the vessel. Seeds were obtained after three successive crystallizations of the raw 6 
material. The same seeds were used for all the seeded experiments: crystals were in the form 7 
of short needles with fairly homogenous width (around 40-60 μm) and variable length (up to 8 
around 200 μm). At the end of the profile, the temperature was kept constant for few hours 9 
(until both FBRM and ATR-UV/Vis signals stabilized); after that, crystals were filtered and 10 
washed with acetone. CryPRINS was used to select the desired heating/cooling rate and to 11 
monitor the UV and FBRM signals during the experiments. In addition to the linear cooling 12 
experiments, three consecutive crystallizations of the same material were conducted using 13 
ethanol and water or pure water as solvents. Recrystallizing the same material more than once 14 
allows obtaining very pure crystals but the overall yield of the process is penalized. These 15 
three experiments were conducted to check the purity that could be obtained by using 16 
multiple steps of crystallization compared to a single linear cooling profile. Table 2 shows the 17 
conditions of the experiments performed in this section. 18 
HPLC analysis 19 
The mobile phase for the HPLC analyses was prepared dissolving 7.4 g of  𝑁𝑁𝑁𝑁2𝐻𝐻𝑃𝑃𝑃𝑃4 ∙ 2𝐻𝐻2𝑃𝑃 20 
(HPLC purity grade, Fisher Scientific) in 740 ml of deionized water (from a Millipore Elix 5) 21 
and then adding 260 ml of methanol (Fisher Scientific). The solution pH was adjusted to 3.5 22 
using 𝐻𝐻3𝑃𝑃𝑃𝑃4 (Fisons analytical reagents). The solid samples were dissolved in purified water 23 
(concentration of about 1 mg/ml). For the detection of the sample constituents the UV 24 
wavelength at 351 nm was used. The flow rate applied was 0.8 ml/min for a total running 25 
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time of 40 min for each sample. The temperature of the column was kept constant at 35 °C 1 
and the injection size was 20 μl. The type of column used was an Analytical Column Waters 2 
Spherisorb® 5μm C8 4.6×250 mm. The main peak at about 14 min corresponds to 3 
cyanocobalamin while the other peaks are byproducts (50-carboxyl cyanocobalamin, 34-4 
mehil cobalamin, 8-Epi- cyanocobalamin, 7β,8β-cyanocobalamin lactate) and other 5 
unspecified impurities. All samples were analyzed at least twice and purity was calculated as 6 
the average relative area of the cyanocobalamin peak. 7 
Principal component analysis on Raman spectroscopic data 8 
Principal components analysis (PCA) is a dimension reduction technique for quantitative 9 
data. Given a set of data in more variables, with PCA it is possible to reduce the dimensions 10 
of the problem down to two or three, keeping at the same time, enough information to capture 11 
the inherent variability within the data. PCA is a method that models all the variations in the 12 
data set using orthogonal basis vectors (eigenvectors) which are called principal components 13 
in this analysis.17 If 𝐴𝐴 is the 𝑛𝑛 ×  𝑚𝑚 matrix of input data (𝑛𝑛 rows of spectra recorded at 𝑚𝑚 14 
wavelengths for example), PCA can decompose it in the following linear system: 15 
𝐴𝐴 = 𝐶𝐶𝑃𝑃𝑇𝑇 + 𝜀𝜀,                     (1) 16 
where 𝐶𝐶 is the 𝑛𝑛 ×  𝑘𝑘 matrix of 𝑘𝑘 principal components’ scores and 𝑃𝑃 is the 𝑚𝑚 ×  𝑘𝑘 matrix 17 
of the eigenvectors of 𝐴𝐴 . The eigenvectors are called “loadings” in PCA. 𝜀𝜀  is a matrix 18 
containing the unexplained variance. Loadings and score for PCA can be used to interpret the 19 
data. The scores are usually represented in two-dimensional scatter plots. Often, a very high 20 
percentage of variability is gathered in the first few principal components so only a few of 21 
these plots are necessary. The scores plots are usually used to detect similarities, differences 22 
or other interesting relationships among samples. A PCA was performed over Raman 23 
spectroscopic data of vitamin B12 in order to determine a relation between the purity of the 24 
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analyzed crystals and their Raman spectra. Matlab 2013a was used for the calculation of the 1 
principal component scores (pca function). 2 
 3 
Results and discussion 4 
Linear cooling experiments 5 
Simple linear cooling was applied to the raw and recrystallized vitamin B12 and the results 6 
were studied using FBRM and images from an optical microscope. The crystal size 7 
distribution (CSD) was found to be strongly affected by the purity of the material used and 8 
the cooling rate. Usually large crystals and a narrow crystal size distribution are preferred 9 
because they facilitate the downstream operations (such as filtration, washing and milling). 10 
For this reason a good quality CSD is characterized by large crystals of similar size. The 11 
solvent used did not have a significant effect on the CSD but it affects the final purity of the 12 
crystals. The effect of seeding was also analyzed and it was found that a slightly purer 13 
material can be obtained at the end of the crystallization using purified seed. Figure 4 shows 14 
the results of experiment 1 and experiment 2 described in Table 2, in which raw vitamin B12 15 
was crystallized from an ethanol/water mixture at two different cooling rates (-0.5 and -16 
0.1 °C/min, fast and slow cooling). From the microscopic images of crystals at the end of the 17 
two experiments (see Figure 4a and Figure 4b) it can be noticed that in both cases the size 18 
distributions look very broad with both small and large crystals; but a considerably larger size 19 
is clearly generated by the slow cooling shown in Figure 4b. This behaviour is similar to what 20 
normally happens for common pharmaceuticals such as paracetamol.18-21 In general, during a 21 
fast cooling experiment, nucleation happens at high superaturation generating a large amount 22 
of small nuclei while in a slow cooling experiment, few nuclei are nucleated at low 23 
supersation. However, for paracetamol, a fast cooling generates a high number of total counts 24 
from the FBRM due to the large number of nucleai generated at high supersaturation. In the 25 
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case of Vitamin B12 the trend seems to be the opposite, as shown in Figure 5a and b. In 1 
experiment 1 (Figure 5a) when slow cooling was used, the number of counts was lower than 2 
in experiment 2 (Figure 5b)  which was conduced at a fast cooling rate. Furthermore, the 3 
images from the microscope seem to contrast with the data from FBRM data since, clearly 4 
less and bigger particles were generated using slow cooling (Figure 4b) compared to fast 5 
cooling (Figure 4a). Additionally, the final square weighted mean chord length distribution is 6 
higher for the fast cooling rate (Figure 5a) than the slow one (Figure 5b). This discrepancy 7 
between images and FBRM data is related to the needle shape of the vitamin B12 crystals. As 8 
the particles grow in length, the shorter size of the crystals is counted by the FBRM more 9 
times than the longer giving the erroneous larger number of counts for small crystal size 10 
present in the vessel. A similar behavior for this probe was observed by Leyssens et al. for a 11 
small needle-like molecule prodrug antagonist called CDP323-2.22  12 
The longer the crystals are, the higher is the value of the total counts recorded by FBRM; and 13 
that is the reason why slow cooling of raw vitamin B12 generated a higher value of the total 14 
counts than fast cooling (70,600 #/meas. in the slow cooling against 44,000 #/meas. as shown 15 
in Figure 4a and 4b). However, considering the large amount of small crystals present at the 16 
end of both experiments (in particular see Figure 4a for experiment 1 and Figure 4c for 17 
experiment 3), it is clear that secondary nucleation prevails on growth for raw vitamin B12. 18 
This can be explained by the fact that the presence of impurities inhibits growth, and 19 
supersaturation is used mainly to nucleate new small crystals.  20 
Some breakage is also present in the slow cooling after 400 min as shown in the CLD 21 
distribution of Figure 5d, where a reduction in the number of larger particles can be observed.  22 
Breakage of crystals also contributed to the higher number of counts in the case of slow 23 
cooling. Figure 6a and 6c show the FBRM and UV data for fast and slow cooling 24 
crystallization of a purified solution of vitamin B12 (experiment 3 and 4 of Table 2). The use 25 
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of recrystallized material with fewer impurities reduced considerably both primary and 1 
secondary nucleation during the cooling phase and promoted growth of the existing crystals.  2 
Figure 6b and 6d show the microscopic images of the resulting crystals; the crystal size 3 
distribution is narrower compared to experiment 1 and 2 and crystals are considerably larger 4 
with the maximum total counts that reaches only 5,200 #/meas. in the fast cooling experiment 5 
and 26,900#/meas. for the slow cooling. The effect of the shape of the crystals on the FBRM 6 
data is clearer in these two experiments because of the absence of breakage or secondary 7 
nucleation; crystals in Figure 6d are clearly longer than the ones shown in Figure 6b and the 8 
CLD (Figure 7a and 7b) present a bimodal shape with a growing peak at low sizes due to the 9 
increasing counts of the shorter size of the crystals.  10 
It is clear that growth of vitamin B12 is strongly inhibited by impurities and very broad 11 
crystal size distributions are generated by secondary nucleation and breakage. Additionally, 12 
in some cases, multiple nucleation events can happen as shown in Figure 8b, c and d, which 13 
is also a clear indication of growth inhibited crystallization processes in the presence of 14 
impurities. Figure 8a shows the results for experiment 5 (Table 2) where vitamin B12 15 
nucleated and grew throughout the entire cooling period. Figure 8b, 8c and 8d instead, show 16 
cases in which a second major nucleation event happened during the cooling phase. The UV 17 
signal dropped suddenly during the second nucleation and the counts increased at the same 18 
time. This phenomenon appeared with both raw and recrystallized material, for seeded and 19 
unseeded experiments and for both the solvents used. During these experiments growth was 20 
so inhibited that supersaturation accumulated during the cooling until it reached a level at 21 
which a second major nucleation event could happen. In these cases the final CLD is very 22 
broad and many small particles are present as a result of this double nucleation as shown in 23 
Figure 9 (for experiment 7).  24 
  25 
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Purity analysis using HPLC and Raman spectroscopy 1 
A first qualitative screening of both the raw material and the crystals obtained by consecutive 2 
crystallizations (with increasing purity as shown in Table 3) was performed using Raman 3 
microscopy. The inert material filtered during the crystallizations was also analyzed. Figure 4 
10a shows the Raman spectra of raw and filtered material; a strong fluorescence, due to 5 
impurities can be noticed (high intensity and no defined peaks). It is interesting to observe 6 
that just the filtration of the hot solution eliminates part of the fluorescent material. A loss of 7 
fluorescence due to less impurity can also be noticed in the samples of the consecutive 8 
crystallizations (Figure 10b). The number and position of the peaks is the same for all the 9 
samples but they tend to become broader and less intense as fluorescence (and, therefore 10 
impurity) increases. In order to have some quantitative information from Raman spectroscopy 11 
a principal component analysis was performed over the Raman spectra of the recrystallized 12 
material, the raw material and the filtered one. Figure 11a shows the score of principal 13 
component PC2 plotted versus the score of principal component PC1. The raw and filtered 14 
material points are isolated and very far from the crystallized samples because of their high 15 
impurity content. Figure 11b shows only the crystallized samples: a clear trend of the scores 16 
as a function of purity is present. This example provides an illustration for the non-17 
conventional use of Raman spectroscopy for monitoring low concentration of impurities 18 
based on fluoresce. While fluorescence is in general undesirable in Raman spectroscopy, 19 
since it makes the interpretation of the significant peaks difficult, monitoring the amount of 20 
fluorescence in the Raman spectra can serve as a method of detecting the existence and 21 
changes in impurity levels in the case of fluorescent impurities.  22 
The loss of impurity during the consecutive crystallizations also considerably improved the 23 
size of the crystals as shown in Figure 12. The raw material showed in Figure 12a is highly 24 
fluorescent and amorphous; particles are very small and hygroscopic and the colour is intense 25 
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red. Crystalline vitamin B12 is darker as shown in Figure 12b to 12d. The mean size of the 1 
crystals increases during the consecutive crystallization as a result of less inhibited growth. 2 
The results of HPLC analyses of the samples from selected experiments out of those 3 
performed are shown in Table 3. A higher purity can be reached if slow cooling rates are 4 
applied and seeding also helps in increasing the purification efficiency. The largest increase 5 
in purity was reached using raw material in an ethanol/water mixture with seeding and slow 6 
cooling (linear cooling experiment 14, increase in purity of 3.65%). The second 7 
crystallizations (using purified material) as expected present a lower increase in purity; 8 
however, even for this set of experiments, slow cooling and seeding helped reaching a higher 9 
purity. The effect of the solvent on the final crystal size distribution is negligible but choosing 10 
the suitable solvent seems to help increasing the purity of the product. It also seems not to 11 
affect purification efficiency since the final purity of similar experiments in different solvents 12 
is very close.  13 
 14 
Conclusions 15 
A set of PAT tools was used to study the crystallization in the presence of impurities of a 16 
small biomolecule produced by fermentation (vitamin B12). Materials produced by 17 
biosynthesis often contain a high amount of impurities that can significantly reduce the 18 
quality of the final crystals in term of size distribution. Multiple successive recrystallizations 19 
of the same material can help eliminating impurities and reaching a better crystal size 20 
distribution, but they also contribute to decrease the yield. Using PAT tools can help 21 
understanding the characteristics of the studied compound and developing a correct 22 
crystallization strategy to improve crystal size and purity of the final product. 23 
It was found that impurities strongly affect the growth rate, promoting nucleation and, in 24 
some cases, generating multiple nucleation events during the cooling profile. The final crystal 25 
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size distribution for these cases was found to be very broad, with very large crystals together 1 
with significant amounts of fines. Slow cooling of very impure material increases the 2 
probability of multiple nucleation events and, therefore, leads to a broad crystal size 3 
distribution. However, slow cooling was found to generate more pure crystals compared to 4 
fast cooling. The best quality of the crystals, in terms of size, was reached using already 5 
crystallized material to prepare the solution and slow cooling rates. Seeding was also found to 6 
help in increasing the purity of the final crystal while a change in the solvent composition did 7 
not largely affect purity or final CSD. The needle shape of the vitamin B12 crystals also had 8 
to be considered before interpreting the FBRM results. The growth of the long size of the 9 
needles generates an increase in the FBRM total counts that can be confused with nucleation. 10 
An analysis of the crystals with the optical microscope was necessary to interpret the counts 11 
and chord length distribution recorded by the FBRM. Monitoring the level of fluorescence 12 
due to impurities in the Raman spectrum, can serve as a method of detecting changes in the 13 
impurity concentrations in the crystalized products.    14 
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Table 1: Solubility of vitamin B12 in water at different temperature (data provided by Hebei Welcome 1 
Pharmaceutical Co., LTD) 2 
Temperature (°C) Solubility (g/l water) 
10 9.25 
20 10 
25 11.5 
30 13.5 
45 24 
 3 
 4 
  5 
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Table 2: Experiment conditions, slow and fast cooling of raw and crystallized material 1 
Experiment 
Solvent Vitamin 
concentration 
(g/g solvent) 
Type of material Cooling rate (°C/min) Seeding 
1 Ethanol/water 0.118 Raw -0.5 (fast cooling) No 
2 Ethanol/water 0.118 Raw -0.1 (slow cooling) No 
3 Water 0.097 Crystallized 
(more than once) 
-0.5 (fast cooling) No 
4 Water 0.097 Crystallized 
(more than once) 
-0.1 (slow cooling) No 
5 Water 0.089 Raw material -0.1 (slow cooling) No 
6 Water 0.106 Crystallized -0.075(slower cooling) No 
7 Water 0.089 Raw material -0.1 (slow cooling) Yes 
8 Water 0.097 Crystallized -0.1 (slow cooling) Yes 
9 Ethanol/water 0.119 Raw -1 (faster cooling) No 
10 Ethanol/water 0.119 Raw -1 (faster cooling) Yes 
11 Ethanol/water 0.119 Raw -0.5 (fast cooling) No 
12 Ethanol/water 0.119 Raw -0.5 (fast cooling) Yes 
13 Ethanol/water 0.119 Raw -0.1 (slow cooling) No 
14 Ethanol/water 0.119 Raw -0.1 (slow cooling) Yes 
15 Ethanol/water 0.13 Crystallized -1 (faster cooling) No 
16 Ethanol/water 0.13 Crystallized -0.5 (fast cooling) No(150 rpm) 
17 Ethanol/water 0.13 Crystallized -0.5(fast cooling) No(240rpm) 
18 Ethanol/water 0.13 Crystallized -0.5 (fast cooling) Yes 
19 Ethanol/water 0.13 Crystallized -0.1 (slow cooling) No 
20 Ethanol/water 0.115 Raw -0.5  No 
21 Ethanol/water 0.137 From exp. 20 -0.5 No 
22 Water 0.082 From exp. 21 -0.5 No 
  2 
20 
 
Table 3: HPLC results for selected experiments performed 1 
Sample 
Purity 
(%) 
Improvement in 
purity (%) 
Solvent used 
Material 
used 
Cooling 
rate 
(°C/min) 
Seeded 
Raw material 93.11 0 n.a. n.a. 
 
n.a. n.a. 
First crystallization 96.14 3.03 n.a. n.a. 
 
n.a. n.a. 
Second 
crystallization 
97.29 1.16 n.a. n.a. 
 
n.a. n.a. 
Third 
crystallization 
98.03 0.74 n.a. n.a. 
 
n.a. n.a. 
LC experiment 8 97.54 1.24 Water Crystallized -0.1 Yes 
LC experiment 9 96.35 3.24 Ethanol/water Raw -1 No 
LC experiment 10 96.28 3.17 Ethanol/water Raw -1 Yes 
LC experiment 11 96.28 3.17 Ethanol/water Raw -0.5 No 
LC experiment 12 96.72 3.61 Ethanol/water Raw -0.5 Yes 
LC experiment 13 96.51 3.40 Ethanol/water Raw -0.1 No 
LC experiment 14 96.76 3.65 Ethanol/water Raw -0.1 Yes 
LC experiment 15 97.66 0.94 Ethanol/water Crystallized -1 No 
LC experiment 16 97.70 0.98 Ethanol/water Crystallized -0.5 No 
LC experiment 17 97.72 1.00 Ethanol/water Crystallized -0.5 No 
LC experiment 18 97.95 1.23 Ethanol/water Crystallized -0.5 Yes 
LC experiment 19 97.77 1.05 Ethanol/water Crystallized -0.1 No 
LC experiment 20 96.14 3.03 Ethanol/Water Raw -0.5 No 
LC experiment 21 97.29 1.16 Ethanol/Water Crystallized 
once 
-0.5 No 
LC experiment 22 98.03 0.74 Water Crystallized 
twice 
-0.5 No 
 2 
  3 
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List of Figures: 1 
Figure 1: Molecular structure of cyanocobalamin. The CN group constitutes the difference 2 
from the natural vitamin B12 and it is the results of the extraction procedure by which the 3 
compound is removed from bacterial cultures.1  4 
Figure 2: schematic of the equipment used during the experiments. 5 
Figure 3: inferential solubility curve expressed as UV signal versus temperature in the two 6 
solvents used. The addition of ethanol increased the solubility of vitamin B12 especially at 7 
high temperature. This type of curve can replace the classical concentration versus 8 
temperature relationship in cases in which only a small amount of material is available and 9 
literature data are not available. 10 
Figure 4: Microscope image of the crystals at the end of experiment 1 (fast cooling) (b) 11 
Microscope image of the bigger crystals at the end of experiment 2 (slow cooling) (c) 12 
Microscope image of the smaller crystals at the end of the experiment 2. 13 
Figure 5: (a) Experiment 1: fast cooling of raw material in water and ethanol, -0.5°C/min. 14 
The graph shows the total counts per measurement and the mean of the square weighted 15 
chord length distribution (MSWCLD) from the FBRM (b) Experiment 2: slow cooling of raw 16 
material in water and ethanol, -0.1°C/min. The graph shows the total counts per measurement 17 
and the mean of the square weighted chord length distribution from the FBRM (c) 18 
Experiment 1: chord length distribution for the fast cooling experiment (d) Experiment 2: 19 
chord length distribution for the slow cooling experiment. 20 
Figure 6: Absorbance value at 361nm, Total counts from FBRM and mean of the square 21 
weighted chord length distribution (MSWCLD) for (a) Experiment 3: fast cooling and 22 
crystallization of purified material dissolved in water (b) Experiment 3: microscopic image of 23 
the final crystals for the fast cooling experiment in water (c) Experiment 4: slow cooling and 24 
22 
 
crystallization of purified material dissolved in water (d) Experiment 4: microscopic image of 1 
the final crystals for the slow cooling experiment in water. 2 
Figure 7: (a) Experiment 3: chord length distribution (CLD) during the fast cooling 3 
experiment in water with purified material (b) Experiment 4: chord length distribution (CLD) 4 
during the slow cooling experiment in water with purified material. 5 
Figure 8: (a) Experiment 5: slow cooling -0.1°C/min of raw material. Total counts per 6 
measurement from FBRM and absorbance from ATR-UV/Vis. (b) Experiment 6: slow 7 
cooling -0.075°C/min of recrystallized material. Total counts per second from FBRM 8 
(Loughborough University) and UV derivative signal. (c) Experiment 7: seeded and slow 9 
cooling of raw material in water (-0.1°C/min) (d) Experiment 8: seeded and slow cooling of 10 
recrystallized material in water (-0.1°C/min). 11 
Figure 9: (a) Chord length distribution (CLD) in the seeded and slow cooling of raw material 12 
in water (Experiment 7) (b) Microscopic image of the final crystals for the seeded and slow 13 
cooling of raw material in water (Experiment 7). 14 
Figure 10: (a) Raman spectra of the raw material donated and the particles filtered at high 15 
temperature (b) Raman spectra of the crystals from the three consecutive crystallizations. A 16 
loss in fluorescence can be noticed. 17 
Figure 11: (a) Score of the second principal component (PC2) plotted against the first 18 
principal component (PC1) for all the samples analysed. (b) Score of the second principal 19 
component (PC2) plotted against the first principal component (PC1) for the crystallized 20 
samples. 21 
Figure 12: microscopic images of (a) Raw vitamin B12 from fermentation (b) Crystal 22 
obtained after the first crystallization (c) Crystal at the end of the second crystallization (d) 23 
Crystals after the third crystallization 24 
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Figure 1: Molecular structure of cyanocobalamin. The CN group constitutes the difference from the natural vitamin 3 
B12 and it is the results of the extraction procedure by which the compound is removed from bacterial cultures.1  4 
 5 
  6 
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Figure 2: schematic of the equipment used during the experiments. 2 
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 1 
Figure 3: inferential solubility curve expressed as UV signal versus temperature in the two solvents used. The 2 
addition of ethanol increased the solubility of vitamin B12 especially at high temperature. This type of curve can 3 
replace the classical concentration versus temperature relationship in cases in which only a small amount of material 4 
is available and literature data are not available.  5 
  6 
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Figure 4: (a) Microscope image of the crystals at the end of experiment 1 (fast cooling) (b) Microscope image of the 6 
bigger crystals at the end of experiment 2 (slow cooling) (c) Microscope image of the smaller crystals at the end of the 7 
experiment 2. 8 
  9 
(a) 
(b) 
(c) 
27 
 
 1 
  2 
 3 
Figure 5: (a) Experiment 1: fast cooling of raw material in water and ethanol, -0.5°C/min. The graph shows the total 4 
counts per measurement and the mean of the square weighted chord length distribution (MSWCLD) from the FBRM 5 
(b) Experiment 2: slow cooling of raw material in water and ethanol, -0.1°C/min. The graph shows the total counts 6 
per measurement and the mean of the square weighted chord length distribution (MSWCLD) from the FBRM (c) 7 
Experiment 1: chord length distribution (CLD) for the fast cooling experiment (d) Experiment 2: chord length 8 
distribution (CLD) for the slow cooling experiment.  9 
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Figure 6: Absorbance value at 361nm, Total counts from FBRM and mean of the square weighted chord length 9 
distribution (MSWCLD) for (a) Experiment 3: fast cooling and crystallization of purified material dissolved in water 10 
(b) Experiment 3: microscopic image of the final crystals for the fast cooling experiment in water (c) Experiment 4: 11 
slow cooling and crystallization of purified material dissolved in water (d) Experiment 4: microscopic image of the 12 
final crystals for the slow cooling experiment in water. 13 
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 1 
Figure 7: (a) Experiment 3: chord length distribution (CLD) during the fast cooling experiment in water with 2 
purified material (b) Experiment 4: chord length distribution (CLD) during the slow cooling experiment in water 3 
with purified material. 4 
 5 
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(b) 
30 
 
 1 
Figure 8: (a) Experiment 5: slow cooling -0.1°C/min of raw material. Total counts per measurement from FBRM and 2 
absorbance from ATR-UV/Vis. (b) Experiment 6: slow cooling -0.075°C/min of recrystallized material. Total counts 3 
per second from FBRM (Loughborough University) and UV absorbance. (c) Experiment 7: seeded and slow cooling 4 
of raw material in water (-0.1°C/min) (d) Experiment 8: seeded and slow cooling of recrystallized material in water (-5 
0.1°C/min). Total counts per measurement from FBRM and absorbance from ATR-UV/Vis. 6 
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Figure 9: (a) Chord length distribution (CLD) in the seeded and slow cooling of raw material in water (Experiment 7) 12 
(b) Microscopic image of the final crystals for the seeded and slow cooling of raw material in water (Experiment 7). 13 
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Figure 10: (a) Raman spectra of the raw material donated and the particles filtered at high temperature (b) Raman 4 
spectra of the crystals from the three consecutive crystallizations. A loss in fluorescence can be noticed. 5 
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Figure 11: (a) Score of the second principal component (PC2) plotted against the first principal component (PC1) for 3 
all the samples analysed. (b) Score of the second principal component (PC2) plotted against the first principal 4 
component (PC1) for the crystallized samples.  5 
  6 
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
-1 -0.8 -0.6 -0.4 -0.2 0PC
2 
sc
or
e 
PC1 score 
Filtered material 1 
Filtered 
material 2 
Raw material 1 
Raw material 2 
-0.04
-0.035
-0.03
-0.025
-0.02
-0.015
-0.01
-0.005
0
-0.03 -0.025 -0.02 -0.015 -0.01 -0.005 0
PC
2 
sc
or
e 
PC1 score 
Increasing 
purity 
(a) 
(b) 
1st crystallization 1 
1st crystallization 2 
2nd crystallization 2 
2nd crystallization 1 
3rd crystallization 1 
3rd crystallization 2 
34 
 
 1 
 2 
Figure 12: microscopic images of (a) Raw vitamin B12 from fermentation (b) Crystal obtained after the first 3 
crystallization (c) Crystal at the end of the second crystallization (d) Crystals after the third crystallization 4 
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